Transforming the Business Structure From Food Development Support to Proprietary Products and Evidence Support
First written in FY2016. 23 of 33 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「As part of the business reorganization, the Group withdrew from the cosmetics business in China, consolidated its domestic cosmetics business and functional materials development business under 日本予防医薬㈱, and shifted to an operating structure that manages health supplements, cosmetics, functional materials development and OEM operations as an integrated business.」
The Group has concretely shifted from a multi-business structure to one in which the domestic cosmetics and functional materials development businesses are consolidated under 日本予防医薬㈱ and operated together with the health supplements business. - FY2026-H1AdvancedAnnual report
「In addition, the Group recorded a gain of ¥96 million on the transfer of trademark rights following the termination of 株式会社ビービーラボラトリーズ' business as an extraordinary gain, a business reorganization loss of ¥131 million related to its structural reform initiatives as an extraordinary loss, and ¥8 million in losses on the reorganization of business sites related to the consolidation of the Kanto office. As a result, profit before income taxes was ¥194 million, compared with a loss before income taxes of ¥212 million in the same period of the previous year.」
As part of the structural reforms, the Kanto office was consolidated, resulting in a business reorganization loss of ¥131 million and business-site reorganization losses of ¥8 million. The disclosure identifies a specific site consolidation associated with the reforms. - FY2025ReframedAnnual report
「Going forward, under a policy of “selection and concentration,” the Group will continue its structural reforms and concentrate management resources in the healthcare business, centered on medical DX.」
The Group has redefined its policy from operating across multiple businesses to continuing structural reforms and concentrating management resources in healthcare, centered on medical DX. - FY2024-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2024-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2024-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2023RestatedAnnual report
「The Group will continue to focus on these businesses, using the expertise, experience and infrastructure it has developed to date in areas where it can make the most of its strengths.」
The Group continues to operate a business structure focused on multiple fields, including its own products, clinical research support, cosmetics and health supplements, in addition to development support such as assessment testing. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2023-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2023-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2022-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2022-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2021-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2021-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2021-Q1RestatedAnnual report
「The Group plans to expand its business by leveraging its track record and know-how in building and applying evidence based on university-developed biomarker technologies, as well as its extensive networks in the medical and healthcare communities, to develop and provide products and services that address social needs in a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2020RestatedAnnual report
「The Group will continue to focus on these businesses, using the expertise, experience and infrastructure it has developed to date in areas where it can make the most of its strengths.」
The Group continues to operate a business structure focused on multiple fields, including its own products, pharmaceutical clinical research support, cosmetics and healthcare, in addition to development support such as assessment testing. - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2020-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2019-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2019-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2019-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2018RestatedAnnual report
「The Group will continue to focus on these businesses, using the expertise, experience and infrastructure it has developed to date in areas where it can make the most of its strengths.」
The business structure continues to expand beyond development support, including proprietary products, pharmaceutical clinical research support and marketing support. - FY2018-Q2RestatedAnnual report
「In addition, from the first quarter of the current consolidated fiscal year, following a change in the Group's business management classifications, all businesses previously included under "Marketing" have been consolidated under "Health Supplements."」
The Group continues to classify its Marketing business under Health Supplements for business management purposes. - FY2018-Q1ReframedAnnual report
「In addition, from the first quarter of the current consolidated fiscal year, following a change in the Group's business management classifications, all businesses previously included in “Marketing” have been consolidated under “Health Supplements.”」
For business management purposes, operations previously classified under Marketing were consolidated under Health Supplements. This was a reclassification for management purposes and does not directly indicate a change in the actual business activities. - FY2017-Q3RestatedAnnual report
「The Group plans to expand its business by leveraging its track record and know-how in building and applying evidence based on university-originated biomarker technology, as well as its extensive networks in the medical and healthcare communities, to develop and provide products and services that meet social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on assessment testing. - FY2017-Q1RestatedAnnual report
「We intend to expand our business by developing and providing products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The group continues to pursue a business structure that provides products and services across multiple fields, including pharmaceuticals, food, cosmetics and healthcare-related services, rather than focusing solely on evaluation testing. - FY2016First statedAnnual report
「The Group seeks to transform its business structure from food development support businesses, including assessment testing, to businesses involving the development and sale of proprietary products, including health supplements, as well as evidence-building and marketing support, including marketing and pharmaceutical clinical research support.」
The policy is to shift the focus from assessment testing toward proprietary products, marketing and pharmaceutical clinical research support.